Philadelphia-The U.S. Preventive Services Task Force has issued a new statement on prostate cancer screening that finds "insufficient scientific evidence to promote routine screening for all men and inconclusive evidence that early detection improves health outcomes."
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.